Pyrrolo[2,3-b]indol-5-ol,1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-methylcarbamate), (3aS,8aR)- cas no:57-47-6

NamePyrrolo[2,3-b]indol-5-ol,1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-methylcarbamate), (3aS,8aR)-
CAS57-47-6
SynonymsPhysostigmine(8CI); Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-,methylcarbamate (ester), (3aS,8aR)- (9CI); Pyrrolo[2,3-b]indol-5-ol,1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-;(-)-Eserine; (-)-Physostigmine; Cogmine; Eserine; Esromiotin; MCV 4484; NIH10421; NSC 30782; Physostol
EINECS(EC#)200-332-8
Molecular FormulaC15H21 N3 O2
Molecular Weight275.3463

refractive index1.567
storage temp2-8°C

Hazardclass6.1(a)

Hazard Toxic by ingestion.
Risk 26/28
Safety

A human poison by an unspecified route. Poison experimentally by ingestion, subcutaneous, intramuscular, intravenous, and intraperitoneal routes. Human systemic effects by ingestion: nausea, dyspnea, coma, blood pressure elevation, flaccid paralysis without anesthesia, muscle weakness. Normally administered by injection. Poisoning can occur as a result of a mistake in dosage or due to hypersensitivity of the patient within 5 to 25 minutes after administration. Death usually results from respiratory paralysis. Experimental reproductive effects. Combustible when exposed to heat or flame. When heated to decomposition it emits toxic fumes of NO_x. See also CARBAMATES.
Hazard Codes T+
Risk Statements 26/28
R26/28:Very toxic by inhalation and if swallowed.
Safety Statements 23-45-25
S23:Do not breathe vapour. 
S25:Avoid contact with eyes. 
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR UN 1544 6.1/PG 1
WGK Germany 3
RTECS TJ2100000
F 8-10
HazardClass 6.1(a)
PackingGroup II

1.		orl-man TDLo:12 mg/kg/60D-I		NEURAI    Neurology. 37 (1987),345.
2.		unr-man LDLo:882 µg/kg		85DCAI    Poisoning; Toxicology, Symptoms, Treatments. 2 (1970),73.
3.		orl-wmn TDLo:40 µg/kg/5D-I:BPR		AJPSAO    American Journal of Psychiatry. 143 (1985),910.
4.		orl-wmn TDLo:3920 µg/kg/2W-I		NEURAI    Neurology. 37 (1987),345.
5.		orl-hmn TDLo:20 mg/kg:CNS,GIT,PUL		34ZIAG    Toxicology of Drugs and Chemicals ,Deichmann, W.B.,New York, NY.: Academic Press, Inc.,1969,475.
6.		ipr-mus LD50:644 µg/kg		FATOAO    Farmakologiya i Toksikologiya (Moscow). 43 (1980),717.
7.		scu-mus LD50:740 µg/kg:PNS		JPETAB    Journal of Pharmacology and Experimental Therapeutics. 123 (1958),121.
8.		ivn-mus LD50:400 µg/kg		JPETAB    Journal of Pharmacology and Experimental Therapeutics. 58 (1936),337.
9.		scu-dog LDLo:1138 µg/kg		FEPRA7    Federation Proceedings, Federation of American Societies for Experimental Biology. 5 (1946),184.
10.		orl-rbt LD50:11,200 µg/kg		DCTODJ